Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen
Drug: Amcenestrant
Drug: Tamoxifen-matching placebo
Drug: Amcenestrant-matching placebo

First Posted Date: 2021-11-22

Last Posted Date: 2023-06-22

Lead Sponsor: Sanofi

Target Recruit Count: 3

Registration Number: NCT05128773

Locations: 🇨🇳
Investigational Site Number :1561599, Haikou, China
🇨🇱
Investigational Site Number :1521622, Santiago, Reg Metropolitana De Santiago, Chile

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

Completed

Conditions: Primary Hypercholesterolaemia and Mixed Dyslipidaemia
Atherosclerotic Cardiovascular Disease

First Posted Date: 2021-11-22

Last Posted Date: 2025-03-24

Lead Sponsor: Sanofi

Target Recruit Count: 163

Registration Number: NCT05129241

Locations: 🇩🇪
Investigational Site Number, Germany, Germany

Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

Phase 1

Terminated

Conditions: Hepatic Function Abnormal

Interventions: Drug: amcenestrant

First Posted Date: 2021-11-19

Last Posted Date: 2022-09-14

Lead Sponsor: Sanofi

Target Recruit Count: 13

Registration Number: NCT05126329

Locations: 🇩🇪
Investigational Site Number :2760001, Kiel, Germany
🇰🇷
Investigational Site Number :4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of
🇰🇷
Investigational site number :4100002, Cheongju-si, Korea, Republic of

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine/Lixisenatide

First Posted Date: 2021-11-10

Last Posted Date: 2024-05-24

Lead Sponsor: Sanofi

Target Recruit Count: 124

Registration Number: NCT05114590

Locations: 🇺🇸
Downtown LA Research Center Inc - ClinEdge - PPDS-Site Number:8400001, Los Angeles, California, United States
🇺🇸
University Clinical Investigators Inc-Site Number:8400020, Tustin, California, United States
🇺🇸
Floridian Research Institute-Site Number:8400013, Miami, Florida, United States

and more 15 locations

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

Phase 2

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: placebo
Drug: rilzabrutinib

First Posted Date: 2021-11-04

Last Posted Date: 2024-07-19

Lead Sponsor: Sanofi

Target Recruit Count: 161

Registration Number: NCT05107115

Locations: 🇪🇸
Investigational Site Number :7240007, Pozuelo de Alarcón, Madrid, Spain
🇪🇸
Investigational Site Number : 7240006, Pamplona, Navarra, Spain
🇪🇸
Investigational Site Number :7240006, Pamplona, Navarra, Spain

and more 125 locations

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Phase 2

Terminated

Conditions: Oesophageal Squamous Cell Carcinoma
Colorectal Cancer
Oesophageal Adenocarcinoma
Gastric Cancer
Hepatocellular Carcinoma

Interventions: Drug: THOR-707
Drug: Pembrolizumab
Drug: Cetuximab

First Posted Date: 2021-11-03

Last Posted Date: 2024-10-02

Lead Sponsor: Sanofi

Target Recruit Count: 138

Registration Number: NCT05104567

Locations: 🇺🇸
Seattle Cancer Care Alliance Site Number : 8400009, Seattle, Washington, United States
🇳🇱
Investigational Site Number : 5280001, Amsterdam, Netherlands
🇮🇹
Investigational Site Number : 3800003, Milano, Italy

and more 26 locations

Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Rilzabrutinib
Drug: placebo

First Posted Date: 2021-11-03

Last Posted Date: 2024-03-07

Lead Sponsor: Sanofi

Target Recruit Count: 196

Registration Number: NCT05104892

Locations: 🇪🇸
Investigational Site Number : 7240004, Santander, Cantabria, Spain
🇧🇬
Investigational Site Number : 1000004, Kozloduy, Bulgaria
🇧🇬
Investigational Site Number : 1000003, Sevlievo, Bulgaria

and more 48 locations

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Phase 4

Recruiting

Conditions: Asthma

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2021-10-28

Last Posted Date: 2025-05-09

Lead Sponsor: Sanofi

Target Recruit Count: 1324

Registration Number: NCT05097287

Locations: 🇧🇬
Investigational Site Number : 1000013, Vratsa, Bulgaria
🇵🇪
Investigational Site Number : 6040002, Lima, Peru
🇵🇪
Investigational Site Number : 6040003, Piura, Peru

and more 235 locations

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Phase 4

Completed

Conditions: Autologous Haematopoietic Stem Cell Transplant

Interventions: Drug: plerixafor + G-CSF

First Posted Date: 2021-10-21

Last Posted Date: 2023-01-31

Lead Sponsor: Sanofi

Target Recruit Count: 53

Registration Number: NCT05087212

Locations: 🇨🇳
Investigational Sites, China, China

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukaemia Refractory
Myelodysplastic Syndromes
Acute Lymphocytic Leukaemia
Blastic Plasmacytoid Dendritic Cell Neoplasia

Interventions: Drug: SAR443579

First Posted Date: 2021-10-20

Last Posted Date: 2025-01-24

Lead Sponsor: Sanofi

Target Recruit Count: 169

Registration Number: NCT05086315

Locations: 🇳🇱
Investigational Site Number :5280002, Amsterdam, Netherlands
🇳🇱
Investigational Site Number :5280003, Groningen, Netherlands
🇳🇱
Investigational Site Number : 5280005, Nijmegen, Netherlands

and more 21 locations

Home Terms & Conditions Privacy Policy